pharma · Advanced Solid Tumors · Agitation Associated with Alzheimer’s Disease
Bristol-Myers Squibb Australia Pty Ltd
Bristol-Myers Squibb Australia is a pharma organization headquartered in Melbourne, AU. Primary therapeutic focus areas include Advanced Solid Tumors, Agitation Associated with Alzheimer’s Disease, BP-I mania or mania wi
Phase 3 · small molecule · Schizophrenia
Xanomeline and Trospium Chloride Capsules (CN012-0008) is an oral small-molecule combination therapy developed by Bristol-Myers Squibb Australia Pty Ltd for the treatment of schizophrenia. The formulation combines xanomeline, a muscarinic acetylcholine receptor agonist, with trospium chloride, an M2 receptor antagonist
Internal code CN012-0008
Xanomeline and Trospium Chloride Capsules (CN012-0008) is an oral small-molecule combination therapy developed by Bristol-Myers Squibb Australia Pty Ltd for the treatment of schizophrenia. The formulation combines xanomeline, a muscarinic acetylcholine receptor agonist, with trospium chloride, an M2 receptor antagonist, designed to address dopaminergic and cholinergic pathways implicated in schizophrenia pathophysiology. The program is currently in Phase 3 development with a latest milestone recorded on 2026-05-05. Trospium chloride is an established component with multiple approved formulations in the United States across multiple manufacturers including Bristol-Myers, Allergan, and others. The combination approach represents a strategy to potentially improve efficacy and tolerability profiles compared to conventional antipsychotics. The program's completion status indicates Phase 3 trials have concluded, positioning the candidate for potential regulatory submission. Specific efficacy data, safety outcomes, and regulatory pathway details remain not yet disclosed.
Schizophrenia remains a significant unmet medical need affecting approximately 1% of the global population, with current antipsychotic therapies limited by variable efficacy, substantial side-effect burdens including metabolic syndrome and extrapyramidal symptoms, and poor long-term adherence rates. The muscarinic-based approach of this combination represents a mechanistically distinct strategy from conventional dopamine antagonists, potentially addressing cognitive symptoms and negative symptoms that respond poorly to standard treatments. The combination of xanomeline with trospium chloride targets both M1/M4 agonism and M2 antagonism, a rationale supported by preclinical evidence suggesting enhanced efficacy with reduced dopaminergic side effects. The competitive landscape includes established agents such as aripiprazole, paliperidone ER, and clozapine, alongside emerging candidates. Bristol-Myers Squibb's development of this combination in a capsule formulation suggests focus on oral bioavailability and patient convenience. The schizophrenia market represents a substantial commercial opportunity, with persistent demand for agents offering improved tolerability and efficacy profiles. Phase 3 completion indicates the program has advanced through substantial clinical evaluation, with regulatory submission potentially imminent depending on trial outcomes and sponsor strategy.
Drug Class: Combination antipsychotic with dual muscarinic modulation
Mechanism of Action: Xanomeline functions as a muscarinic acetylcholine receptor agonist (M1/M4 selective); trospium chloride acts as a muscarinic M2 receptor antagonist. This dual approach aims to enhance dopaminergic tone in prefrontal cortex while limiting M2-mediated feedback inhibition.
Modality: Small-molecule oral capsule formulation
Route of Administration: Oral
Target: Muscarinic acetylcholine receptors (M1, M2, M4)
Related Therapies: Conventional antipsychotics (dopamine D2 antagonists: aripiprazole, paliperidone); atypical antipsychotics (clozapine, iloperidone); emerging muscarinic-based approaches
Regulatory Status of Trospium Chloride Component: Approved in the United States under multiple manufacturers and application numbers (NDA021595, NDA022103, NDA216158, and multiple ANDAs); established safety and pharmacokinetic profile
Patent Status: Not yet disclosed
Also known as: schizophrenia 12, schizophrenia (disease), SCZD
A major psychotic disorder characterized by abnormalities in the perception or expression of reality. It affects the cognitive and psychomotor functions. Common clinical signs and symptoms include delusions, hallucinations, disorganized thinking, and retreat from reality.
ClinicalTrials.gov lists 2,921 registered studies for Schizophrenia (AACT aggregate).
Phase breakdown: NA (1,441), PHASE4 (414), PHASE3 (377), PHASE2 (297), PHASE1 (276), PHASE1/PHASE2 (52), PHASE2/PHASE3 (42), EARLY_PHASE1 (22)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0005090), Orphanet — schizophrenia, NCT00000371, NCT00000372, NCT00000374, NCT00000387, NCT00001192, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 3 trials initiated
Phase 3 clinical development program for schizophrenia indication commenced; primary trial NCT05145413 registered.
Latest program milestone
Most recent milestone recorded; Phase 3 program status noted as completed.
The schizophrenia treatment landscape includes multiple established and emerging competitors. Conventional antipsychotics such as aripiprazole (Otsuka Beijing Research Institute) and paliperidone ER (Hospital Authority, Hong Kong) remain standard-of-care agents with extensive clinical evidence and generic availability. Atypical antipsychotics including clozapine (Bright Minds Biosciences) and iloperidone (Vanda Pharmaceuticals) offer alternative mechanisms but with variable tolerability profiles. Emerging candidates include PERSERIS (Indivior, long-acting formulation), INTENSIFY SZ (Disc Medicine), and adjunctive agents such as valbenazine (Neurocrine Biosciences) for tardive dyskinesia management. Vortioxetine (Takeda) and ramelteon (Takeda) represent alternative neurobiological approaches. The xanomeline-trospium combination's muscarinic-based mechanism differentiates it from dopamine-centric competitors, potentially addressing cognitive and negative symptom domains inadequately treated by conventional agents. However, the competitive field remains crowded with established, well-tolerated agents and multiple pipeline candidates. Bristol-Myers Squibb's positioning emphasizes the dual muscarinic modulation strategy as a mechanistically distinct approach to improve efficacy-tolerability balance.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| Clozapine | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| Iloperidone | Vanda Pharmaceuticals Netherlands B.V. | small_molecule | approved |
| Ramelteon | Takeda | small_molecule | approved |
| PERSERIS | Indivior Pty Ltd | small_molecule | approved |
| INTENSIFY SZ | Disc Medicine | small_molecule | approved |
| Varenicline | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| Aripiprazole | Otsuka Beijing Research Institute | small_molecule | approved |
| Paliperidone ER | Hospital Authority, Hong Kong | small_molecule | approved |
| Vortioxetine | Takeda | small_molecule | approved |
| Valbenazine | NEUROCRINE BIOSCIENCES INC | small_molecule | approved |
| Minocycline | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| Dexmedetomidine | BioXcel Therapeutics | small_molecule | approved |
| ZIPRASIDONE HYDROCHLORIDE | — | Dopamine D2 receptor antagonist | Approved |
| TRIFLUOPERAZINE HYDROCHLORIDE | — | D2-like dopamine receptor antagonist | Approved |
| THIOTHIXENE | — | Dopamine D2 receptor antagonist | Approved |
| SAMIDORPHAN L-MALATE | — | Delta opioid receptor partial agonist | Approved |
| RISPERIDONE | — | Serotonin 2a (5-HT2a) receptor antagonist | Approved |
| QUETIAPINE FUMARATE | — | Serotonin 2c (5-HT2c) receptor antagonist | Approved |
| PROCHLORPERAZINE | — | Dopamine D2 receptor antagonist | Approved |
| PERPHENAZINE | — | Dopamine D2 receptor antagonist | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States (FDA): Trospium chloride component holds multiple approved applications (NDA021595, NDA022103, NDA216158) with established regulatory history. The combination formulation CN012-0008 regulatory status not yet disclosed; Phase 3 completion suggests potential pathway toward New Drug Application (NDA) submission pending trial outcomes.
European Medicines Agency (EMA): Regulatory status not yet disclosed.
PMDA (Japan): Regulatory status not yet disclosed.
NMPA (China): Clinical trial activity noted with multiple NCT registrations (NCT04201275, NCT06558656, NCT07327281, NCT04796623, NCT06524804, NCT01941576) indicating ongoing or completed clinical evaluation in China. Specific NMPA approval status not yet disclosed.
Key Regulatory Considerations: Trospium chloride's established safety profile may facilitate regulatory review of the combination. Phase 3 completion status indicates substantial clinical data generation; regulatory submission timeline and pathway remain not yet disclosed.
Xanomeline and Trospium Chloride Capsules is being developed for the treatment of schizophrenia. It combines two active components targeting muscarinic acetylcholine receptors to address dopaminergic and cholinergic pathways implicated in schizophrenia pathophysiology.
The combination formulation is not yet approved. It is currently in Phase 3 development. Trospium chloride, one of the components, is an approved medication with multiple manufacturers in the United States.
Xanomeline acts as a muscarinic acetylcholine receptor agonist (M1/M4 selective), while trospium chloride acts as an M2 receptor antagonist. This dual approach aims to enhance dopaminergic tone in the prefrontal cortex while limiting feedback inhibition.
Bristol-Myers Squibb Australia Pty Ltd is the sponsor and developer of this combination therapy for schizophrenia.
The program is in Phase 3 development with a latest milestone recorded on May 5, 2026. Phase 3 trials have been completed, positioning the candidate for potential regulatory submission.
Multiple clinical trials are registered, including the primary Phase 3 trial NCT05145413 and additional trials in China (NCT04201275, NCT06558656, NCT07327281, NCT04796623, NCT06524804, NCT01941576). Specific results have not yet been reported.
Trospium chloride is a muscarinic M2 receptor antagonist. In this combination, it works to reduce M2-mediated feedback inhibition, enhancing the overall dopaminergic effects of the xanomeline component.
Xanomeline is a muscarinic acetylcholine receptor agonist with selectivity for M1 and M4 receptors. It is designed to enhance cognitive and antipsychotic effects through these receptor subtypes.
The drug is administered orally as a capsule formulation, designed to provide patient convenience and improve adherence compared to injectable alternatives.
The indication is schizophrenia, a severe mental health disorder affecting approximately 1% of the global population with significant unmet medical needs for improved efficacy and tolerability.
Yes, multiple approved schizophrenia treatments exist, including aripiprazole, paliperidone ER, clozapine, iloperidone, and other conventional and atypical antipsychotics. The muscarinic-based mechanism of this combination represents a mechanistically distinct approach.
The internal program code is CN012-0008, assigned by Bristol-Myers Squibb Australia Pty Ltd.
No development partner is disclosed for this program. Bristol-Myers Squibb Australia Pty Ltd is the sole sponsor.
Multiple clinical trials are registered in China, indicating ongoing or completed clinical evaluation. Specific NMPA approval status has not yet been disclosed.
The dual muscarinic modulation mechanism differentiates this candidate from dopamine-centric competitors, potentially addressing cognitive and negative symptoms inadequately treated by conventional antipsychotics, though efficacy advantages require clinical demonstration.
Approval timeline is not yet disclosed. Phase 3 completion in 2026 suggests potential regulatory submission within 12-24 months, contingent on positive trial outcomes and regulatory review timelines.
Peak sales projections have not yet been disclosed by the sponsor or analyst consensus.
Xanomeline and Trospium Chloride Capsules → Drug → Target → Indication → Company → Trials → Competitors
Development Strategy: Bristol-Myers Squibb's advancement of this muscarinic-based combination to Phase 3 completion reflects confidence in the dual M1/M4 agonism plus M2 antagonism mechanism for schizophrenia. The oral capsule formulation prioritizes patient convenience and adherence compared to injectable alternatives.
Competitive Positioning: The mechanistic differentiation from dopamine antagonists positions this candidate to potentially address unmet needs in cognitive and negative symptom domains. However, the crowded competitive landscape with established agents and multiple pipeline candidates necessitates clear efficacy and tolerability advantages for market penetration.
Regulatory Pathway: Phase 3 completion in 2026 suggests potential NDA submission within 12-24 months, contingent on positive trial outcomes. The established safety profile of trospium chloride may facilitate regulatory review timelines.
Clinical Data Gaps: Specific efficacy endpoints, safety profiles, and comparative data versus standard-of-care agents remain not yet disclosed. Publication of Phase 3 results will be critical for competitive positioning and regulatory strategy.
Future Catalysts: (1) Phase 3 trial results publication; (2) NDA submission announcement; (3) Regulatory feedback or approval decision; (4) Potential label expansion studies; (5) Commercial partnership announcements.
Market Considerations: Schizophrenia market remains substantial but competitive. Success will depend on demonstrated advantages in efficacy, tolerability, or specific symptom domains versus entrenched competitors and emerging alternatives.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.